Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02232022 · ClinicalTrials.gov registry record · NA
Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
A NA study of Ischemic Stroke, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 2
- Study locations
NCT02232022: Completed NA study of Ischemic Stroke, sponsored by Northwell Health.
NCT02232022 is a NA study of Ischemic Stroke that has completed, run by Northwell Health. The registered enrollment target is 53 participants, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02232022, a NA study of Ischemic Stroke, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.
Primary Outcome
The incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.
Conditions Studied
Interventions
- DEVICE Reveal LINQ Insertable Cardiac Monitor
Study Locations (2)
New York
- North Shore University Hospital - Manhasset
- Long Island Jewish Medical Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-09-01 |
| Est. Completion | 2017-09-28 |
| Phase | NA |
What the finished NCT02232022 record still lists
NCT02232022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,463-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Reveal LINQ Insertable Cardiac Monitor is the first listed.
NCT02232022 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02232022 about?
NCT02232022 is a clinical study titled "Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke". The purpose of this study is to determine the incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.
What is the current status of trial NCT02232022?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2014-09-01. Estimated completion is 2017-09-28.
What conditions does trial NCT02232022 study?
This clinical trial studies the following conditions: Ischemic Stroke.
What interventions are being tested in trial NCT02232022?
The interventions under investigation include: Reveal LINQ Insertable Cardiac Monitor (DEVICE).
Who is sponsoring clinical trial NCT02232022?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02232022 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02232022's enrollment target sits among peer trials
53 43rd of 66 higher than 24 of 66 other Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Of Vagus Nerve Stimulation (VNS) With Mobility Training For Gait Recovery After Chronic Ischemic Stroke
RECRUITING · NA
-
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
RECRUITING · NA
-
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
StrokeNet Thrombectomy Endovascular Platform
RECRUITING · NA
-
Virtual Reality Based Rehabilitation After Ischemic Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI